Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 8;58(1):2100221.
doi: 10.1183/13993003.00221-2021. Print 2021 Jul.

The burden of progressive fibrotic interstitial lung disease across the UK

Thomas Simpson  1 , Shaney L Barratt  2   3 , Paul Beirne  4 , Nazia Chaudhuri  5 , Anjali Crawshaw  6 , Louise E Crowley  6 , Sophie Fletcher  7 , Michael A Gibbons  8 , Philippa Hallchurch  2 , Laura Horgan  4 , Ieva Jakaityte  8 , Thomas Lewis  2 , Tom McLellan  9 , Katherine J Myall  1 , Ryan Miller  8 , David J F Smith  10 , Stefan Stanel  5 , Muhunthan Thillai  9 , Fiona Thompson  7 , Timothy Wallis  7 , Zhe Wu  10   11 , Philip L Molyneaux  10   11   12 , Alex G West  1   12
Affiliations

The burden of progressive fibrotic interstitial lung disease across the UK

Thomas Simpson et al. Eur Respir J. .

Abstract

Almost 15% of new referrals with non-IPF fibrotic ILD go on to develop a progressive fibrotic phenotype and would benefit from antifibrotic therapy https://bit.ly/3uPhClN

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: T. Simpson reports non-financial support (educational support/leadership course) from Boehringer Ingelheim, outside the submitted work. Conflict of interest: S.L. Barratt reports grants, personal fees and non-financial support for meeting attendance from Boehringer Ingelheim, outside the submitted work. Conflict of interest: P. Beirne reports personal fees for consultancy and non-financial support for meeting attendance from Boehringer Ingelheim Pharmaceuticals, outside the submitted work. Conflict of interest: N. Chaudhuri reports grants and personal fees for consultancy from Boehringer Ingelheim, personal fees for consultancy from Roche, outside the submitted work. Conflict of interest: A. Crawshaw has received honoraria from Boehringer Ingelheim for educational meetings (chair/talks) and grants for virtual attendance at international conferences. Conflict of interest: L.E. Crowley has nothing to disclose. Conflict of interest: S. Fletcher has nothing to disclose. Conflict of interest: M.A. Gibbons has served on advisory boards and received support to attend conferences from Roche and Boehringer Ingelheim. Conflict of interest: P. Hallchurch has nothing to disclose. Conflict of interest: L. Horgan has nothing to disclose. Conflict of interest: I. Jakaityte has nothing to disclose. Conflict of interest: T. Lewis has nothing to disclose. Conflict of interest: T. McLellan reports unrestricted educational grants from Boehringer Ingelheim, outside the submitted work. Conflict of interest: K.J. Myall has nothing to disclose. Conflict of interest: R. Miller has nothing to disclose. Conflict of interest: D.J.F. Smith has nothing to disclose. Conflict of interest: S. Stanel has nothing to disclose. Conflict of interest: M. Thillai has nothing to disclose. Conflict of interest: F. Thompson has nothing to disclose. Conflict of interest: T. Wallis has nothing to disclose. Conflict of interest: Z. Wu has nothing to disclose. Conflict of interest: P.L. Molyneaux, via his institution, received industry–academic funding from AstraZeneca and has received speaker and consultancy fees from Boehringer Ingelheim and Hoffman-La Roche, outside the submitted work. Conflict of interest: A.G. West has nothing to disclose.

Figures

FIGURE 1
FIGURE 1
Kaplan–Meier curves comparing survival between patients with idiopathic pulmonary fibrosis (IPF), progressive fibrotic interstitial lung diseases (PF-ILD) and non-progressive non-IPF fibrotic lung diseases (non PF-ILD). Log-rank p test value is reported.
See this image and copyright information in PMC

References

    1. Brown KK, Martinez FJ, Walsh SLF, et al. . The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J 2020; 55: 2000085. doi:10.1183/13993003.00085-2020 - DOI - PMC - PubMed
    1. Cottin V, Hirani NA, Hotchkin DL, et al. . Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev 2018; 27: 180076. doi:10.1183/16000617.0076-2018 - DOI - PMC - PubMed
    1. Cottin V. Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases. Eur Respir Rev 2019; 28: 190109. doi:10.1183/16000617.0109-2019 - DOI - PMC - PubMed
    1. Flaherty KR, Wells AU, Cottin V, et al. . Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 2019; 381: 1718–1727. doi:10.1056/NEJMoa1908681 - DOI - PubMed
    1. Olson AL, Gifford AH, Inase N, et al. . The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype. Eur Respir Rev 2018; 27: 180077. doi:10.1183/16000617.0077-2018 - DOI - PMC - PubMed

Publication types

MeSH terms